LU92681I9 - - Google Patents

Info

Publication number
LU92681I9
LU92681I9 LU92681C LU92681C LU92681I9 LU 92681 I9 LU92681 I9 LU 92681I9 LU 92681 C LU92681 C LU 92681C LU 92681 C LU92681 C LU 92681C LU 92681 I9 LU92681 I9 LU 92681I9
Authority
LU
Luxembourg
Application number
LU92681C
Other languages
French (fr)
Other versions
LU92681I2 (fr
Inventor
Gerald Jürgen Roth
Armin Heckel
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Rainer Walter
Meel Jacobus Van
Norbert Redemann
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92681(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU92681I2 publication Critical patent/LU92681I2/xx
Publication of LU92681I9 publication Critical patent/LU92681I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU92681C 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate LU92681I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
LU92681I2 LU92681I2 (fr) 2015-05-18
LU92681I9 true LU92681I9 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2019-01-03

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92681C LU92681I2 (fr) 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate

Country Status (42)

Country Link
EP (2) EP1224170B9 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (2) JP4021664B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (2) KR100857734B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN100455568C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR026036A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AT (1) ATE439342T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU781939B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (1) BE2015C018I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BG (1) BG65983B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BRPI0014735B8 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2387013C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CO (1) CO5261488A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (2) CY1110067T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CZ (1) CZ301073B6 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DE (1) DE50015711D1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK1224170T5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (1) EA006080B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EE (1) EE05427B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EG (1) EG25931A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (1) ES2331459T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (1) FR15C0024I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HK (1) HK1052505B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20020306B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (2) HU230416B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (2) IL148756A0 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (1) LU92681I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ME (1) MEP45408A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MXPA02002799A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY127956A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL300725I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (3) NO322746B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (1) NZ518489A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20010671A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL207445B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (1) PT1224170E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (1) RS51013B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SA (1) SA01210704B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI1224170T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SK (1) SK287312B6 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI268922B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UA (1) UA75054C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2001027081A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
DK1401415T3 (da) 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
WO2003004007A2 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
DE60216281T2 (de) 2001-06-29 2007-07-05 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003027102A1 (en) * 2001-09-27 2003-04-03 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
JP2010529161A (ja) * 2007-06-12 2010-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドリノン誘導体及び癌等の症状を治療する際のそれらの使用
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
TWI432424B (zh) * 2007-12-03 2014-04-01 Boehringer Ingelheim Int 製造吲哚啉酮衍生物之方法
CN102056609B (zh) 2008-06-06 2012-12-05 贝林格尔.英格海姆国际有限公司 药物组合
AR072538A1 (es) * 2008-07-29 2010-09-01 Boehringer Ingelheim Int Derivados de indolinonas, composiciones farmacéuticas y usos
JP2012515184A (ja) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
IN2014DN06869A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2012-01-26 2015-05-22 Angion Biomedica Corp
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CN104936944B (zh) 2012-12-06 2017-09-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3027026B1 (en) 2013-07-31 2024-11-13 Avalyn Pharma Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
SG11201700855XA (en) 2014-08-28 2017-03-30 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR20250020678A (ko) 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
CN114010787A (zh) 2015-06-06 2022-02-08 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
FI3722291T3 (fi) 2015-12-24 2023-09-05 Respivert Ltd Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
JP7039480B2 (ja) 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
US20190160054A1 (en) 2016-04-13 2019-05-30 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
EP3463225A4 (en) 2016-06-02 2020-03-11 Cloudbreak Therapeutics, LLC COMPOSITIONS AND METHODS FOR USE OF NINTEDANIB FOR IMPROVING SUCCESS IN GLAUCOSURGERY
JP6885629B2 (ja) 2016-07-29 2021-06-16 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インドリノン化合物の使用
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
EP3600322A1 (en) 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3700529B1 (en) 2017-10-23 2025-07-09 Boehringer Ingelheim International GmbH New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
WO2019226864A1 (en) 2018-05-25 2019-11-28 Scott Whitcup A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
KR20210068479A (ko) * 2018-10-05 2021-06-09 아이크노스 사이언스 에스.에이. Map4k1 억제제로서의 사용을 위한 인돌리논 화합물
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
EP4541368A3 (en) 2021-01-25 2025-07-02 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
TWI857798B (zh) * 2023-09-28 2024-10-01 國立臺灣大學 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) * 1956-06-08
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5977130A (en) * 1996-01-17 1999-11-02 Taiho Pharmeutical Co., Ltd. Intimal hypertrophy inhibitors
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
TWI268922B (en) 2006-12-21
CN100455568C (zh) 2009-01-28
FR15C0024I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-04-17
CN1391557A (zh) 2003-01-15
KR20020038949A (ko) 2002-05-24
EP2157081A1 (de) 2010-02-24
HRP20020306B1 (en) 2010-09-30
DE50015711D1 (de) 2009-09-24
ES2331459T3 (es) 2010-01-05
SK6462002A3 (en) 2002-08-06
KR100857734B1 (ko) 2008-09-10
HUP0204587A3 (en) 2004-07-28
BRPI0014735A (pt) 2002-07-16
HUS1600022I1 (hu) 2017-02-28
EG25931A (en) 2012-10-24
EP1224170A1 (de) 2002-07-24
HK1052505A1 (zh) 2003-09-19
EP1224170B1 (de) 2009-08-12
YU26602A (sh) 2004-11-25
HUP0204587A2 (en) 2003-05-28
EP1224170B9 (de) 2017-11-22
CZ301073B6 (cs) 2009-10-29
FR15C0024I2 (fr) 2016-08-26
HK1052505B (zh) 2009-06-26
UA75054C2 (uk) 2006-03-15
JP2003511441A (ja) 2003-03-25
EA006080B1 (ru) 2005-08-25
JP2007302697A (ja) 2007-11-22
NL300725I2 (nl) 2017-07-13
NO322746B1 (no) 2006-12-04
DK1224170T5 (en) 2018-01-22
EA200200380A1 (ru) 2002-10-31
DK1224170T3 (da) 2009-12-07
NO2015009I1 (no) 2015-03-30
CA2387013C (en) 2009-12-29
BRPI0014735B1 (pt) 2012-07-10
NO2015009I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-03-18
CY1110067T1 (el) 2015-01-14
KR100835546B1 (ko) 2008-06-09
BG65983B1 (bg) 2010-08-31
SK287312B6 (sk) 2010-06-07
BRPI0014735B8 (pt) 2021-07-06
WO2001027081A1 (de) 2001-04-19
MXPA02002799A (es) 2003-02-27
NZ518489A (en) 2005-05-27
RS51013B (sr) 2010-10-31
BG106587A (bg) 2003-01-31
AU781939B2 (en) 2005-06-23
NO20021719L (no) 2002-04-11
SI1224170T1 (sl) 2009-12-31
IL148756A0 (en) 2002-09-12
CY2015009PI1 (el) 2016-12-14
CA2387013A1 (en) 2001-04-19
MY127956A (en) 2007-01-31
PL207445B1 (pl) 2010-12-31
LU92681I2 (fr) 2015-05-18
JP4021664B2 (ja) 2007-12-12
KR20070095996A (ko) 2007-10-01
PE20010671A1 (es) 2001-06-28
PT1224170E (pt) 2009-10-01
NO2023033I1 (no) 2023-09-05
CY2015009PI2 (el) 2016-12-14
PL355433A1 (pl) 2004-04-19
CO5261488A1 (es) 2003-03-31
SA01210704B1 (ar) 2006-12-05
EE05427B1 (et) 2011-06-15
HRP20020306A2 (en) 2003-10-31
EE200200197A (et) 2003-06-16
IL148756A (en) 2007-10-31
CZ20021410A3 (cs) 2002-07-17
NO20021719D0 (no) 2002-04-11
HU230416B1 (hu) 2016-05-30
BE2015C018I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2019-10-23
AU1023301A (en) 2001-04-23
ATE439342T1 (de) 2009-08-15
MEP45408A (en) 2011-02-10
AR026036A1 (es) 2002-12-26

Similar Documents

Publication Publication Date Title
FR15C0024I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2013C020I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2013C015I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2013C001I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2012C036I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2011C004I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE1025464I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2008C046I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002518668A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2010C011I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002505423A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002502043A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE2008C047I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002519539A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002531762A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002523158A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002528201A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP2002514538A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IN191232B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IN191363B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BRPI9917761A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BRPI0303609A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN3098701S (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN3097656S (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN3098433S (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)